Stock Detail
The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.
Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.
At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com), and Niagen Plus™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription.
Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published.
†Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024).
Videos
ChromaDex Corp. (CDXC) Company Webcast
This company webcast features ChromaDex Corp. (Nasdaq: CDXC). ChromaDex is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. This company webcast was recorded during the Lytham Partners 2025 Investor...
ChromaDex Corporation (CDXC) Fireside Chat
During this fireside chat Ben Shamsian, Vice President, Lytham Partners and Sean McGowan, Roth Capital Partners, chat with Rob Fried, Chief Executive Officer of ChromaDex Corporation. ChromaDex (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide...
News
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms
Exclusively licensed from Queen's University Belfast (QUB), this composition of matter patent, one of the most robust forms of intellectual property protection, grants Niagen Bioscience exclusive rights to various salt forms of NR and derivatives LOS ANGELES - Niagen...
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science
The rebrand celebrates the company's clinically proven flagship patented nicotinamide riboside (NR) ingredient, Niagen, the most well-researched, efficient, high-quality, and legal NAD+ booster available LOS ANGELES - Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly...
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol “NAGE” Effective March 19, 2025
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it will change its corporate name to Niagen Bioscience, Inc. and trade under the new Nasdaq...